GU Cancers 2026 | Using early QoL data to identify patients with high-risk RCC
Michael Harrison, MD, Duke University School of Medicine, Durham, NC, discusses the correlation between early changes in patient data and survival rates in patients with metastatic renal cell carcinoma (RCC) receiving immunotherapy-based combinations, highlighting the importance of clinicians monitoring both baseline and early changes at three and six months. Patients with poor quality of life are at higher risk and should be watched more closely, with potential consideration for intensified therapy. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think we’re just starting to understand how this looks in the real world. So we have this data from these trials, and now we’re trying to essentially replicate it in the real world. So our next analysis will look at how can we correlate these early changes with early deaths, so in other words, a version of survival. And so I think the take home is probably that clinicians should be paying attention to both baseline and early changes at three and six months...
I think we’re just starting to understand how this looks in the real world. So we have this data from these trials, and now we’re trying to essentially replicate it in the real world. So our next analysis will look at how can we correlate these early changes with early deaths, so in other words, a version of survival. And so I think the take home is probably that clinicians should be paying attention to both baseline and early changes at three and six months. And thinking about for those patients who have a poor quality of life, those are the patients that you want to watch more closely. And whether or not we can do things like intensify therapy, that remains to be seen. But those seem to be higher risk patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
